http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 07:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+Investor+Conferences+in+September+2026/26977315.html <p>MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:</p> <p><strong>Event</strong>:<em>12</em>^<em>th</em><em> Annual Cantor Global Healthcare Conference</em> <br /><strong>Location</strong>: New York, NY<br /><strong>Date &amp; Time</strong>: September 10, 2026 at 2:10 pm ET<br /><strong>Format</strong>: Fireside Chat</p> <p><strong>Event</strong>: The Morgan Stanley 24th Annual Global Healthcare Conference<br /><strong>Location</strong>: New http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+Investor+Conferences+in+September+2026/26977315.html Wed, 26 Aug 2026 07:30:00 -0400 EIKN http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+Investor+Conferences+in+September+2026/26977315.html <p>MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that Roger M. Perlmutter, M.D., Ph.D., Chairman and Chief Executive Officer, and Freddie Bowie, Ph.D., Chief Financial Officer, will participate in two upcoming investor conferences taking place in September:</p> <p><strong>Event</strong>:<em>12</em>^<em>th</em><em> Annual Cantor Global Healthcare Conference</em> <br /><strong>Location</strong>: New York, NY<br /><strong>Date &amp; Time</strong>: September 10, 2026 at 2:10 pm ET<br /><strong>Format</strong>: Fireside Chat</p> <p><strong>Event</strong>: The Morgan Stanley 24th Annual Global Healthcare Conference<br /><strong>Location</strong>: New http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+Investor+Conferences+in+September+2026/26977315.html Wed, 26 Aug 2026 07:30:00 -0400 EIKN http://www.streetinsider.com/Analyst+Comments/Eikon+Therapeutics+%28EIKN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26958709.html <p>Cantor Fitzgerald analyst Imogen Mansfield reiterated an Overweight rating on Eikon Therapeutics Inc. (NASDAQ: EIKN).</p><p>The analyst commented, "EIKN is pursuing combinations for EIK1003 paclitaxel, carboplatin/ paclitaxel (both in multiple solid tumors), and abiraterone (in metastatic prostate cancer). EIK1004, EIKN's brain penetrant program, has monotherapy data upcoming at ESMO but EIKN plans to pursue a similar broad combination strategy. This asset has a particularly interesting opportunity in breast cancer, where BRCA mutant disease is at high risk of metastasizing to the brain."</p><p>For an analyst ratings summary and ratings history on Eikon Therapeutics Inc. <a href="http://www.streetinsider.com/rating_history.php?q=EIKN">click here</a>. For more ratings news on http://www.streetinsider.com/Analyst+Comments/Eikon+Therapeutics+%28EIKN%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+/26958709.html Fri, 21 Aug 2026 08:29:05 -0400 EIKN http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html <p>MILLBRAE, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced that its Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026, at 9:00 AM ET, hosted by Cantor Fitzgerald and featuring Dr. Timothy A. Yap, MBBS, PhD, FRCP, medical oncologist and physician scientist from the University of Texas MD Anderson Cancer Center.</p> <p>Dr. Timothy A. Yap currently serves as Vice http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+to+Participate+in+KOL+Event+on+Therapeutic+Use+of+PARP+Inhibitors+in+Oncology+Hosted+by+Cantor+Fitzgerald/26944394.html Tue, 18 Aug 2026 16:15:00 -0400 A.33662632 A.60000185 EIKN O.00165169 O.20228465 O.49773468 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26923982.html si-local-file:///var/storage/secattach/20260814/26923982.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26923982.html Fri, 14 Aug 2026 06:07:00 -0400 EIKN O.49773468 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26923982.html si-local-file:///var/storage/secattach/20260814/26923982.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26923982.html Fri, 14 Aug 2026 06:07:00 -0400 EIKN O.49773468 http://www.streetinsider.com/Earnings/Eikon+Therapeutics%2C+Inc.+%28EIKN%29+Misses+Q2+EPS+by+163c/26922604.html <p>Eikon Therapeutics, Inc. (NASDAQ: EIKN) reported Q2 EPS of ($1.63), $1.63 worse than the analyst estimate of $0.00.</p><p>For earnings history and earnings-related data on Eikon Therapeutics, Inc. (EIKN) <a href="http://www.streetinsider.com/ec_earnings.php?q=EIKN">click here</a>.</p> http://www.streetinsider.com/Earnings/Eikon+Therapeutics%2C+Inc.+%28EIKN%29+Misses+Q2+EPS+by+163c/26922604.html Thu, 13 Aug 2026 17:06:14 -0400 EIKN http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Eikon+Therapeutics%2C+Inc.++For%3A+Jun+30/26921124.html si-local-file:///var/storage/secattach/20260813/26921124.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Eikon+Therapeutics%2C+Inc.++For%3A+Jun+30/26921124.html Thu, 13 Aug 2026 16:11:00 -0400 EIKN O.49773468 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Eikon+Therapeutics%2C+Inc.++For%3A+Jun+30/26921124.html si-local-file:///var/storage/secattach/20260813/26921124.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Eikon+Therapeutics%2C+Inc.++For%3A+Jun+30/26921124.html Thu, 13 Aug 2026 16:11:00 -0400 EIKN O.49773468 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26920907.html si-local-file:///var/storage/secattach/20260813/26920907.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26920907.html Thu, 13 Aug 2026 16:08:00 -0400 EIKN O.49773468 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26920907.html si-local-file:///var/storage/secattach/20260813/26920907.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Eikon+Therapeutics%2C+Inc.++For%3A+Aug+13/26920907.html Thu, 13 Aug 2026 16:08:00 -0400 EIKN O.49773468 http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26920563.html <ul><li><em>Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005</em><br /></li><li><em>Presented data at the American Society for Clinical Oncology (ASCO) 2026 Annual Meeting </em><em>demonstrating encouraging activity of EIK1001 combined with pembrolizumab and histology-appropriate chemotherapy for the front-line treatment of patients with advanced NSCLC in the TeLuRide-005 Phase 2 trial, and preliminary evidence that the PARP1-selective inhibitor EIK1003 could be safely combined with full-dose paclitaxel in second-line treatment of breast and ovarian cancers</em><br http://www.streetinsider.com/Press+Releases/Eikon+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26920563.html Thu, 13 Aug 2026 16:02:00 -0400 EIKN http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26920563.html <ul><li><em>Eikon announced seven abstracts accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026 highlighting progress across Eikon’s oncology portfolio, including clinical updates for EIK1001 and EIK1003 and initial clinical findings for EIK1004 and EIK1005</em><br /></li><li><em>Presented data at the American Society for Clinical Oncology (ASCO) 2026 Annual Meeting </em><em>demonstrating encouraging activity of EIK1001 combined with pembrolizumab and histology-appropriate chemotherapy for the front-line treatment of patients with advanced NSCLC in the TeLuRide-005 Phase 2 trial, and preliminary evidence that the PARP1-selective inhibitor EIK1003 could be safely combined with full-dose paclitaxel in second-line treatment of breast and ovarian cancers</em><br http://www.streetinsider.com/Globe+Newswire/Eikon+Therapeutics+Reports+Second+Quarter+2026+Financial+Results+and+Provides+Clinical+Updates/26920563.html Thu, 13 Aug 2026 16:02:00 -0400 EIKN http://www.streetinsider.com/FDA/Eikon+picks+dose+for+phase+23+melanoma+trial+of+EIK1001/26901431.html <p>Eikon Therapeutics, Inc. (Nasdaq: EIKN) has selected a dose of 0.60 mg/m² for all patients randomized to receive EIK1001 in its ongoing TeLuRide-006 trial, a global, adaptive Phase 2/3 study evaluating the drug candidate in advanced cutaneous melanoma.</p> <p>The dose selection followed a prespecified analysis of unblinded data and a recommendation from an independent Data Monitoring Committee (DMC). The DMC also recommended the trial continue as planned in all other respects.</p> <p>TeLuRide-006 is a multicenter, randomized, double-blind registrational trial testing EIK1001 or placebo in combination with pembrolizumab as a first-line therapy for patients with advanced cutaneous melanoma.</p> <p>EIK1001 is an investigational, systemically administered http://www.streetinsider.com/FDA/Eikon+picks+dose+for+phase+23+melanoma+trial+of+EIK1001/26901431.html Tue, 11 Aug 2026 07:30:24 -0400 EIKN